The San Antonio Breast Cancer Symposium is held each year in San Antonio, Texas, about a fortnight or so before Christmas. It is the largest international breast cancer meeting and it aims to mix laboratory research with clinical research. The following were important topics at this symposium. Some of the reports are potentially practice changing.
In this review:
Three trials examining extended adjuvant endocrine therapy with AIs in early breast cancer
Therapeutic options for AI-resistant metastatic breast cancer
Studies evaluating tumour infiltrating lymphocytes
Outcomes in sporadic and hereditary BC – does BRCA affect outcome in young patients?
Abemaciclib - a phase II neoadjuvant study into biological and clinical effects
Duloxetine for AI-associated musculoskeletal symptoms
A phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with EBC
Please login below to download this issue (PDF)